Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prasugrel crossover study in atherosclerosis
ACTRN12612001157864Phase 4Completed
- Sponsor
- Capital and Coast District Health Board
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of prasugrel in atherosclerosis (2 arms), sponsored by Capital and Coast District Health Board. Primary endpoint: Difference in interferon gamma production by CD4 T cells. Started Jun 2013; status: completed.
02
Drugs
prasugrel
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on ACTRN12612001157864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612001157864.